Throat cancer is relatively uncommon compared to cancers of the breast, lung, or colon, but it still affects a significant number of people each year. In the United States, an estimated 60,480 new cases of oral cavity and pharynx cancer will be diagnosed in 2026, with roughly 13,150 deaths. Laryngeal cancer, which affects the voice box specifically, is even less frequent, ranking as the 20th most common cancer worldwide.
Incidence by the Numbers
“Throat cancer” isn’t a single disease. It’s an umbrella term covering cancers of the larynx (voice box), the pharynx (the tube behind the nose and mouth), and sometimes the upper esophagus. Each subtype has its own frequency. Laryngeal cancer occurs at a rate of about 2.6 new cases per 100,000 people per year in the U.S. when both sexes are combined. Hypopharyngeal cancer, which forms in the lower part of the throat, is rarer still, with only about 2,500 new cases diagnosed annually in the U.S., or 0.6 cases per 100,000 people.
Oropharyngeal cancer, which develops in the middle part of the throat including the base of the tongue and tonsils, has been rising in recent decades and now makes up a growing share of head and neck cancer diagnoses. This shift is largely driven by human papillomavirus (HPV), which is linked to roughly 70% of oropharyngeal cancers.
Who Gets Throat Cancer
Men are far more likely to develop throat cancer than women. For laryngeal cancer specifically, the rate in men is 4.3 per 100,000 compared to 0.9 per 100,000 in women, making men nearly five times more likely to be diagnosed. The median age at diagnosis is 67, and cases are uncommon before age 40.
This gender gap is partly explained by historically higher rates of smoking and heavy alcohol use among men, though the disparity persists even as those habits have shifted. HPV-related oropharyngeal cancers also skew heavily male, affecting men at roughly four times the rate of women.
Geographic Patterns
Throat cancer rates vary widely around the world. Asia accounts for 56% of all new laryngeal cancer cases globally, largely due to the continent’s massive population and high rates of tobacco and alcohol use in certain regions. Europe follows at 21%, with North America at 7%.
When adjusted for population size, Cuba has the highest laryngeal cancer rate in the world at 8.3 per 100,000 people. For men specifically, Cuba’s rate reaches 14.8 per 100,000, more than three times the U.S. male rate. The Caribbean broadly stands out as a high-incidence region, driven by heavy tobacco use and other local risk factors.
What Drives the Risk
Tobacco use is the single biggest risk factor for laryngeal and hypopharyngeal cancers. Smoking, chewing tobacco, and even regular exposure to secondhand smoke all increase risk. Alcohol compounds the effect: people who both smoke and drink heavily face a risk many times higher than those who do neither, because alcohol appears to make throat tissues more vulnerable to the carcinogens in tobacco.
HPV infection, particularly type 16, has become the dominant driver of oropharyngeal cancers. About 70% of these cancers test positive for HPV. This is the main reason oropharyngeal cancer rates have been climbing even as smoking rates have declined. HPV-related throat cancers tend to occur in younger patients and carry a better prognosis than those caused by tobacco.
Survival Rates by Stage and Location
Outcomes depend heavily on where in the throat the cancer forms and how far it has spread at diagnosis. Cancers caught while still localized to their original site have meaningfully better survival than those that have reached nearby lymph nodes or distant organs.
For cancer of the glottis (the vocal cords), the five-year survival rate is 85% when localized, dropping to 56% with regional spread and 48% when distant. Vocal cord cancers tend to be caught earlier because even small tumors cause noticeable hoarseness.
Cancers above the vocal cords (the supraglottis) and below them (the subglottis) have lower survival rates, around 60% when localized and 48 to 50% with regional spread. These areas don’t produce early symptoms as reliably, so tumors often grow larger before detection.
Hypopharyngeal cancer has the most concerning numbers: 61% five-year survival when localized, but only 36% with regional spread and 20% when distant. This location is particularly difficult because the hypopharynx sits deep in the throat, and tumors there tend to remain silent until they’ve grown substantially.
How HPV Is Changing the Picture
The rise of HPV-related oropharyngeal cancer has reshaped who gets throat cancer and how it behaves. These cancers often appear in people with no significant history of smoking or drinking, typically men in their 40s and 50s. A common first sign is a painless lump in the neck from a swollen lymph node, which can be mistaken for something benign.
The good news is that HPV-positive oropharyngeal cancers respond better to treatment than HPV-negative ones, with five-year survival rates often exceeding 80%. HPV vaccination, now widely recommended for adolescents, is expected to reduce these cancers over the coming decades, though the impact won’t be fully visible for years because of the long lag between HPV infection and cancer development.
Early Warning Signs
Throat cancer symptoms vary by location but commonly include persistent hoarseness or voice changes lasting more than two weeks, difficulty or pain when swallowing, a sore throat that won’t resolve, ear pain on one side, unexplained weight loss, or a lump in the neck. Many of these overlap with far more common conditions like infections or acid reflux, which is why throat cancer often isn’t the first thing considered.
Hoarseness is the most reliable early signal for laryngeal cancer because even tiny tumors on the vocal cords disrupt voice production. For pharyngeal cancers, a persistent sensation of something stuck in the throat or one-sided symptoms (pain in one ear, a lump on one side of the neck) tend to be more concerning than symmetrical discomfort, which is more typical of infections.